Nycomed Second Quarter 2009 Results

Sustained momentum

Second Quarter 2009 highlights

Highlights presented on a comparable basis[(1)]

- Total net turnover increased 0.5% to €786.9 million (comparable Q2 2008: €783.3 million)[(1)]
- Adjusted EBITDA increased 2.5% to €254.8 million (comparable Q2 2008: €248.7 million)[(1)]
- Turnover of Key Products excluding Pantoprazole grew by 6.9%[(1)]
- Pantoprazole OTC received European marketing authorisation
- Daxas® marketing authorisation applications filed in May for Europe and in July for the US. Forest Laboratories will commercialise Daxas in the United States.
- Instanyl® approved in EU in July for breakthrough cancer pain

Key figures

	Q2 2009 (€m)	Q2 2008 (€m)	Change	H1 2009 (€m)	H1 2008 (€m)	Change
Net turnover	786.9	884.2[(2)] 783.3[(1)]	-11.0%[(2)] +0.5%[(1)]	1,626.8	1,714.5[(2)] 1,613.6[(1)]	-5.1%[(2)] +0.8%[(1)]
Gross profit	576.0	681.6	-15.5%	1,198.0	1,295.8	-7.5%
Margin	73.2%	77.1%	-5.0%	73.6%	75.6%	-2.6%
Operating profit (EBIT)	74.7	178.7	-58.2%	205.6	261.7	-21.5%
EBITDA	249.3	335.9[(2)] 235.0[(1)]	-25.8%[(2)] +6.1%[(1)]	551.3	634.5[(2)] 533.6[(1)]	-13.1%[(2)] +3.3%[(1)]
Margin	31.7%	38.0%[(2)]	-16.6%[(2)]	33.9%	37.0%[(2)]	-8.4%[(2)]
Adjusted EBITDA	254.8	349.6[(2)] 248.7[(1)]	-27.1%[(2)] +2.5%[(1)]	561.8	653.7[(2)] 552.8[(1)]	-14.1%[(2)] +1.6%[(1)]
Margin	32.4%	39.5%[(2)]	-18.1%[(2)]	34.5%	38.1%[(2)]	-9.4%[(2)]

For full results and an explanation of adjusted EBITDA, please see page 12.
[(1)] Excluding a one-time execution payment of €100.9 million from Sepracor in H1 2008.
[(2)] Including the Sepracor payment in 2008

Håkan Björklund, CEO, commented on the company's second quarter performance:

"Nycomed achieved sustained momentum in 2009, with second quarter net turnover up 0.5% excluding the impact of the Sepracor execution payment received in the first half of 2008.

Pantoprazole performed ahead of our expectations, with broadly stable sales despite patent losses in most European markets in May. This reaffirms our confidence in our ability to generate sustained long-term turnover from the product. In June, Pantoprazole OTC received European marketing authorisation and its launch is an important part of our strategy to carefully manage the Pantoprazole franchise.

The second quarter also saw important advances in our pipeline. Daxas, our innovative therapy for the treatment of chronic obstructive pulmonary disease, was filed for approval in Europe in early May and in the US in July. We are also very pleased to have agreed with Forest Laboratories on the US commercialisation of Daxas. We believe they are the best partner for Nycomed in this key market. In July our product Instanyl was approved in Europe, offering an important new option for the treatment of breakthrough pain in cancer patients.

The current global downturn continues to have an impact on our business, particularly on the sales of OTC products in the emerging markets. The trading environment will remain challenging for the full year, but we believe our strategy of identifying and in-licensing promising new products and expanding our focus on emerging markets such as the Asia-Pacific region positions us well for continued success in 2009 and beyond."

Financial Highlights

Total reported net turnover in the quarter decreased 11.0% to €786.9 million, compared to €884.2 million in the second quarter of 2008. In Q2 2008, we reported a one-time execution payment of €100.9 million from Sepracor. Adjusting for this, total net turnover increased by 0.5%, underlining the solid performance of Pantoprazole and other Key Products. Currency movements adversely affected the results.

Net turnover in the first half of 2009 was down 5.1% on a reported basis, to €1,626.8 million (H1 2008: €1,714.5 million). Excluding the effects of currency and the Sepracor execution payment in 2008, total net turnover increased by 2.2%.

Key Products excluding Pantoprazole performed very well, gaining 6.9% in the second quarter year-on-year. Global net turnover of Pantoprazole was broadly stable despite losses of exclusivity in Canada and Europe, down 1.3% in the first half. Pantoprazole OTC received European marketing authorisation during the second quarter and was launched in Germany in July. Excluding the Sepracor execution payment, net turnover of Specialty and Respiratory products increased in the second quarter by 4.4% and 24.8% respectively.

On a regional basis, most of our markets performed in line with or above our expectations, despite uncertainty created by the global economic downturn. Total net turnover in Europe decreased 9.3%. While net turnover in Russia/CIS was up 16.3% in the quarter (+25.3% in local currencies), we anticipate that these markets will remain challenging this year as a result of difficult local economic conditions.

Net turnover in Latin America was up 10.3% on a local currency basis and roughly stable at -0.5% on a reported basis. Strong growth of 14.4% was achieved in the Asia-Pacific, Africa, Middle East region. Net turnover in North America declined by 8.7%, reflecting the impact of generic Pantoprazole in Canada, which was partially offset by a 10.0% increase in Nycomed US turnover.

Excluding the Sepracor execution payment, adjusted EBITDA for the second quarter of this year grew by 2.5% to €254.8 million (Q2 2008: €248.7 million, excluding Sepracor payment).

For the first six months of 2009, adjusted EBITDA decreased by 14.1% to €561.8 million (first half 2008: €653.7 million). Excluding the one-time effect in Q2 2008, adjusted EBITDA increased by 1.6% in the respective period.

Adjusting for both currency effects and the Sepracor payment, adjusted EBITDA increased by 1.8% in the second quarter and by 3.4% in the first six months.

Total costs for the first half of 2009 remained flat, benefiting from a significant decrease in research and development costs (-17.2%), while marketing and sales expenses increased slightly.

Business Review

Regional overview

Region	Net Turnover Q2 2009 (€m)	Net Turnover Q2 2008 (€m)	Change	Change in local currencies	Net Turnover H1 2009 (€m)	Net Turnover H1 2008 (€m)	Change	Change in local currencies
Europe	390.3	430.5	-9.3%	-7.2%	846.8	876.1	-3.3%	-1.3%
Latin America	72.0	72.4	-0.5%	+10.3%	143.4	149.6	-4.2%	+9.0%
Russia/CIS	79.6	68.4	+16.3%	+25.3%	158.3	144.4	+9.7%	+19.5%
Asia-Pacific, Africa, Middle East	47.2	41.2	+14.4%	+13.6%	91.7	77.7	+18.0%	+20.6%
North America	104.5	114.5	-8.7%	-17.3%	202.7	227.0	-10.7%	-16.2%
Outlicensing	73.8	140.5	-47.4%	-49.7%	145.8	204.1	-28.6%	-33.1%
Contract Manufacturing	19.5	16.7	+15.8%	+21.0%	38.1	35.6	+6.7%	+11.2%
Total	**786.9**	**884.2**	**-11.0%**	**-10.7%**	**1,626.8**	**1,714.5**	**-5.1%**	**-3.9%**
Total excl. Sepracor	*786.9*	*783.3*	*+0.5%*	*+1.0%*	*1,626.8*	*1,613.6*	*+0.8%*	*+2.2%*

Overall turnover grew 0.5% during the second quarter, and 0.8% during the first half, excluding the €100.9 million execution payment received from Sepracor during 2008. Solid performances were achieved in Russia/CIS, Latin America, and Asia-Pacific, Africa, Middle East.

Europe

Total European turnover declined in the second quarter by 9.3% to €390.3 million, compared to the same period in 2008, and by 7.2% in local currencies. As expected, the expiry of the Pantoprazole substance patent negatively impacted sales particularly in Germany, Austria and Denmark, while regaining rights to Inipomp® led to a 6.4% increase in turnover in France. Sales in Greece increased 15.8% year-on-year, largely from Pantoprazole and the progress of Preotact®. Eastern Europe was adversely affected by the economic downturn mainly because consumers reduced out of pocket spending on OTC products.

In the first half of 2009, total net turnover in Europe declined by 3.3% to €846.8 million, and by 1.3% in local currencies.

Latin America

Latin America performed well, with net turnover growing 10.3% in local currencies and declining 0.5% on a reported basis to €72.0 million in the second quarter compared to the previous year. In Venezuela, the regained rights to Pantoprazole continued to materially lift sales there. Mexico and Argentina continued to outperform the market, mainly due to strong growth in the gastroenterology field. Sales in Brazil remained broadly flat.

In the first half of 2009, total net turnover in Latin America increased by 9.0% in local currencies and declined by 4.2% to €143.4 million on a reported basis.

Russia/CIS

Despite the economic downturn, sales in Russia/CIS picked up in the second quarter, increasing 16.3% year-on-year to €79.6 million on a reported basis and 25.3% in local currencies. Strong growth emanated both from Rx (26.9% at constant exchange rates) and OTC (13.1%) Looking ahead, we anticipate that the trading environment will remain challenging for the rest of 2009. Local economies continue to struggle as a result of the economic downturn.

In the first half of 2009, total net turnover in Russia/CIS was up 9.7% to €158.3 million, and increased by 19.5% in local currencies.

Asia-Pacific, Africa, Middle East

Total net turnover from Asia-Pacific, Africa, Middle East increased by 14.4% in the second quarter of 2009 compared to 2008, helped by sales of Pantoprazole in Australia, which were up 28.7% at constant exchange rates. As previously announced, Nycomed acquired the remaining shares in its South African subsidiary and is now a 100% shareholder of the company.

In the first half of 2009, total net turnover in Asia-Pacific, Africa, Middle East was up 18.0% to €91.7 million, and increased by 20.6% in local currencies.

North America

Net turnover in North America for the second quarter was down by 8.7% to €104.5 million versus the prior year, largely from continuing generic erosion of Pantoprazole in Canada. Nycomed US turnover in the first half of 2009 increased by 27.4% (10.1% in local currency). In the second quarter net turnover in local currency decreased by 5.0%, due to a delayed start of the snakebite season.

In the first half of 2009, total net turnover in North America declined by 10.7% to €202.7 million, and by 16.2% in local currencies.

Outlicensing

Excluding the execution payment of €100.9 million from Sepracor in 2008, Outlicensing sales grew by 86.4%, driven by increased Pantoprazole sales to Wyeth due to the positive impact of Wyeth's own generic and higher delivery of branded Protonix®.

In the first half of 2009, total Outlicensing net turnover excluding the Sepracor execution payment was up 41.3%.

Contract Manufacturing

Second quarter net turnover from Contract Manufacturing was up 15.8% at €19.5 million on the year, helping Nycomed to utilise excess capacity.

In the first half of 2009, net turnover from Contract Manufacturing increased by 6.7%.

Product net turnover

Area	Net Turnover Q2 2009 (€m)	Net Turnover Q2 2008 (€m)	Change	Change in local currencies	Net Turnover H1 2009 (€m)	Net Turnover H1 2008 (€m)	Change	Change in local currencies
Gastrointestinal	316.2	320.7	-1.4%	-1.6%	678.3	687.4	-1.3%	-1.0%
Specialty Products	126.4	121.1	+4.4%	+6.5%	249.2	230.0	+8.3%	+10.4%
Respiratory	20.8	117.5	-82.3%	-82.0%	46.6	133.0	-64.9%	-64.0%
Subtotal Key Products	463.4	559.3	-17.2%	-16.7%	974.1	1,050.4	-7.3%	-6.3%
OTC*	73.3	81.0	-9.6%	-3.2%	161.5	181.1	-10.9%	-3.7%
Regional and local Rx	164.2	165.7	-0.9%	-9.0%	323.3	351.2	-8.0%	-2.7%
Nycomed US	86.0	78.2	+10.0%	-5.0%	167.9	131.8	+27.4%	+10.1%
Total	**786.9**	**884.2**	**-11.0%**	**-10.7%**	**1,626.8**	**1,714.5**	**-5.1%**	**-3.9%**
Total OTC	**91.3**	**97.5**	**-6.4%**	**+0.8%**	**198.0**	**215.0**	**-7.9%**	**-2.2%**
Respiratory excl. Sepracor	*20.8*	*16.7*	*+24.8%*	*+42.6%*	*46.6*	*32.1*	*+45.2%*	*+64.0%*
Subtotal Key Products excl. Sepracor	*463.4*	*458.4*	*+1.1%*	*+1.7%*	*974.1*	*949.5*	*+2.6%*	*+3.7%*
Total excl. Sepracor	*786.9*	*783.3*	*+0.5%*	*+1.0%*	*1,626.8*	*1,613.6*	*+0.8%*	*+2.2%*

* Not including Calcium OTC (part of Specialty) and Pantoprazole OTC (part of Gastrointestinal)

Key Products excluding Pantoprazole performed well, gaining 6.9% in the second quarter year-on-year. Excluding the execution payment of €100.9 million from Sepracor, the Respiratory portfolio gained 45.2% in the first half. Challenging economic conditions continued to affect OTC net turnover. With an increase of 4.4% in the second quarter year-on-year and of 8.3% for the first half year, Nycomed's Specialty Products continued their growth, notably Preotact (+27.0% in the first half) and TachoSil (up 14.4% in the first six months).

Pantoprazole

Pantoprazole continued its strong performance. In spite of the loss of the substance patent in major EU markets, total turnover declined only slightly, down 1.4% during the second quarter. Turnover in Canada decreased steeply due to generic competition. This was offset by growth in US sales and positive development in Asia-Pacific, Africa, Middle East and Latin America.

The product lost its SPC (supplementary protection certificate) protection at the beginning of May in ten European markets, including major markets such as Germany and France.

European sales of Pantoprazole in the second quarter declined by 11.7%, which is moderate for a product losing exclusivity – and is slightly better than our expectations. These positive results are primarily due to the successful launches of Pantoprazole varieties that compete on price with generic proton pump inhibitors in Germany and Belgium, and which have gained significant market share in just a few months. Furthermore, the entry of generics in Germany helped the molecule pantoprazole (i.e., sales of Nycomed and generics taken together) to increase its market share to 34% of units sold (from 22%), at the expense of other generic proton pump inhibitors, such as omeprazole. Nycomed's Pantoprazole varieties benefited from this overall trend.

In our Latin American markets, Pantoprazole shows a continued good performance, with turnover up 22.0% year-on-year, despite a negative exchange rate impact.

Pantoprazole OTC

Pantoprazole OTC received marketing authorisation for Europe in June and was launched in Germany at the beginning of July, with encouraging initial sales data. Nycomed will launch the product in further European markets in the coming months.

Pantoprazole Pediatric Extension

The FDA granted a Pediatric Extension for the Pantoprazole substance patent in February, extending exclusivity in the United States until January 2011 (previously July 2010).

Pantoprazole US

Nycomed and its licensee Wyeth remain convinced of the validity and enforceability of its US Pantoprazole patent and will continue to pursue litigation vigorously.

Product Portfolio Update

Daxas® filed in Europe and USA

Nycomed filed marketing authorisation applications for Daxas® in Europe in May and in the US after the period end in July, as a once-daily oral treatment for patients with COPD. Subject to approval by the regulatory authorities, the first launches of the product are expected in 2010.

Nycomed and Forest Laboratories to collaborate on US commercialisation of Daxas® in COPD

On August 10, Nycomed and Forest Laboratories, Inc. (NYSE: FRX) announced that they have entered into an exclusive development, manufacturing and commercialisation agreement in the United States for Daxas®. Nycomed will retain marketing rights to Daxas® in Europe and the rest of the world.

Under the terms of the agreement, Forest Laboratories will make an upfront payment of US$100 million and additional milestone payments to Nycomed based on defined regulatory and commercialisation achievements. Nycomed will also receive royalties on US net sales typical for a product which is in registration. Forest Laboratories will assume responsibility for the US regulatory approval and commercialisation of Daxas® in the United States and the companies will collaborate on future development programs. Other details of the financial terms of the agreement were not disclosed.

Instanyl® approved

On July 24, Instanyl® (intranasal fentanyl) was approved in Europe for managing breakthrough pain in adult cancer patients who are already receiving maintenance opioid therapy for chronic pain. Nearly half of all early-stage cancer patients with chronic pain and up to 90% in later stages suffer the sudden onset of brief but acute ‘breakthrough’ pain. Nycomed plans to launch Instanyl® in the first countries starting in autumn 2009.

Acquisition of CEE portfolio from Sanofi-Aventis and Zentiva

In July, Nycomed agreed with Sanofi-Aventis and Zentiva to purchase 20 branded generic products in several Central and Eastern European (CEE) countries. The agreement will notably strengthen Nycomed’s market position, particularly in the Czech Republic and Slovakia. The transaction received approvals from the European Commission and the Czech Antimonopoly Office, and it is expected to close in September 2009.

In an asset transfer transaction, Nycomed will purchase a portfolio of branded generic products in the Czech Republic, Slovakia, Romania, Hungary, Estonia, and Bulgaria, with a total annual turnover of approximately €17 million. Nycomed will also assume production in the coming years. Both parties agreed not to disclose further details on the transaction.

Pantoprazole OTC

See previous page.

Financial Report

Net Turnover

Net turnover for the second quarter 2009 fell by 11.0% to €786.9 million. This decline is solely attributable to the one-time effect of an execution payment from Sepracor in Q2 2008. Excluding this effect, net turnover increased 0.5% compared to last year's 2nd quarter.

Half-year turnover decreased by 5.1% to €1,626.8 million. Excluding the above mentioned one-time effect in 2008, turnover during the first half increased by 0.8%

Excluding currency fluctuations and eliminating the one-time effect in 2008, net turnover increased by 2.2% which underlines the solid performance of the main product Pantoprazole and other Key Products. For more details, please refer to the Business Review with regional overview (page 3) and product turnover (page 6).

Cost of sales

Cost of sales for the period from April to June 2009 increased 4.1% to €210.8 million compared to the same period last year. As a percentage of net sales the cost of goods sold increased to 27.3% from 26.2% in Q2 2008. This is the result of a shift in the product portfolio as well as considerably higher volumes for Pantoprazole in Europe.

For the first six months of 2009 cost of goods sold increased 2.4% to €428.8 million. Cost of goods sold increased by 1.1 percentage-points to an average of 26.7% for this period.

Operating expenses

Operating expenses for the second quarter of 2009 are slightly below last year's second quarter, mainly driven by a decrease in R&D expenses of €13.1 million to €50.9 million. This was partially offset by an increase in marketing and sales expenses of €7.2 million to €240.3 million.

Half year operating expenses remained flat compared to the same period last year.

Financial Items

Financial expenses amounted to €148.9 million during the first six months of 2009. This included interest expenses of €126.9 million and is €116.0 million below the comparable period of 2008. This was mainly caused by reduced interest expenses of €40.3 million and a reduction of unrealised foreign exchange losses of €71.2 million during the first half of 2009.

Financial income for this period amounted to €176.2 million, which is €23.4 million higher than last year due to realised foreign exchange gains.

Net result of the period

Net result for the second quarter 2009 was €74.4 million, an increase of €50.2 million.

For the first six months, the net result of €162.1 million was €82.3 million above the first half of 2008 as a result of the improved financial items.

Adjusted EBITDA

Adjusted EBITDA, which is an important measurement of the Group's performance, was €254.8 million during the second quarter 2009. This was €94.8 million below the same period last year, due to the execution payment from Sepracor received in 2008. Eliminating this effect, adjusted EBITDA showed an increase of 2.5%.

For the first half of 2009 adjusted EBITDA amounted to €561.8 million, which is 14.1% below the first six months last year. Eliminating the prior mentioned one-time effect, the adjusted EBITDA increased by 1.6%.

Adjusting for both currency effects and the Sepracor payment, adjusted EBITDA increased by 1.8% in the second quarter and by 3.4% in the first half.

Cash flow

Net Cash flow from operating activities showed an inflow of €378.2 million for the first half of 2009 compared to an inflow of €479.7 million in the same period of 2008. The decrease in cash flow from operating activities was primarily related to the one-time execution payment received from Sepracor. €103.9 million was paid in taxes during the first six months of 2009.

Cash flow from investing activities showed an outflow of €74.3 million between January and June 2009 compared to €284.5 million for in the same period 2008. This was due to the acquisition of Bradley in the US in 2008 whereas in the same period in 2009 only the remaining 50% of the Joint Venture in South Africa had been acquired. The outflow related to tangible and intangible assets is equivalent to €67.8 million.

Cash flow from financing activities showed an outflow of €348.9 million, €43.6 million more than in the first half of 2008. This is attributable to debt buy back of €92.6 million partially offset by lower interest payments.

Capital Resources

Nycomed will generate significant cash flow during 2009 to support its business strategy and service its debt.

As at the end of June 2009, Nycomed had a cash position of €453.3 million compared to a cash position of €374.1 million at the end of June 2008.

Total senior debt at the end of June 2009 amounted to €4,292.8 million (excluding the effect of outstanding financing fees of €63.2 million and local debt of €0.7 million) compared to €4,455.9 million compared to June 2008. The decrease reflects the scheduled repayment of long-term debt offset by the strengthening of the US dollar against the euro.

Nycomed has committed facilities of €450.0 million under the in-licensing / restructuring facility, of which €125.0 million has been utilised. In addition, Nycomed has a revolver facility of €250.0 million, which remains undrawn.

Income Statement

	Q2 2009 (€m)	Q2 2008 (€m)	H1 2009 (€m)	H1 2008 (€m)
Net sales	773.6	774.7	1,603.3	1,586.8
Royalties / other income	13.3	109.5	23.5	127.6
Net turnover	786.9	884.2	1,626.8	1,714.5
Cost of sales	(210.8)	(202.6)	(428.8)	(418.6)
Gross profit	576.0	681.6	1,198.0	1,295.8
Sales and marketing expenses	(240.3)	(233.1)	(472.9)	(455.5)
Amortisation of fair value adjustments on patents and rights from acquisitions	(141.7)	(131.1)	(283.1)	(320.8)
Total sales and marketing expenses	(382.0)	(364.2)	(756.0)	(776.4)
Research and development expenses	(50.9)	(64.0)	(98.4)	(118.8)
Administrative expenses	(61.7)	(60.9)	(125.3)	(119.8)
Integration / restructuring costs	(6.8)	(13.7)	(12.7)	(19.1)
Operating profit	74.7	178.7	205.6	261.7
Financial income	76.2	(5.8)	176.2	152.8
Financial expenses	(48.4)	(107.8)	(148.9)	(264.9)
Profit / loss before tax	102.4	65.1	232.8	149.6
Income tax	(28.0)	(41.0)	(70.8)	(69.8)
Net result of the period	74.4	24.2	162.1	79.8
Attributable to:				
Equity holders of the parent	–	–	158.2	77.7
Minority interests	–	–	3.9	2.1

EBITDA/ADJUSTED EBITDA				
Net income (loss)	74.4	24.2	162.1	79.8
Adjustments:				
Net financial items	(27.8)	113.6	(27.3)	112.1
Income tax expense (benefit)	28.0	41.0	70.8	69.8
Depreciation and amortisation	174.6	157.2	345.7	372.8
EBITDA	249.3	335.9	551.3	634.6
Adjustments:				
Integration/restructuring costs (exclude depreciation already in EBITDA)	5.5	13.7	10.5	19.1
Inventory step-up	–	–	–	–
Warrants	–	–	–	–
Adjusted EBITDA	254.8	349.6	561.8	653.7

Balance Sheet

	30.6.2009 (€m)	31.12.2008 (€m)
ASSETS		
Non-current assets		
Patents and rights and currently marketed products	*2,671*	*2,956*
Goodwill	*2,162*	*2,159*
Development projects in progress	*511*	*487*
Total intangible assets	5,345	5,602
Total property, plant and equipment	617	624
Other investments in shares and bonds	*32*	*32*
Other receivables	*7*	*8*
Other non current assets	39	39
Deferred tax assets	68	97
TOTAL NON-CURRENT ASSETS	**6,069**	**6,362**
Current assets		
Total inventories	498	435
Trade receivables	547	579
Income tax receivable	31	18
Other receivables / other current assets	63	70
Marketable Securities	*7*	*12*
Cash	*453*	*497*
Total cash and cash equivalents	460	509
TOTAL CURRENT ASSETS	**1,599**	**1,610**
TOTAL ASSETS	7,668	7,972

EQUITY AND LIABILITIES		
Capital stock	17	17
Reserves	1,441	1,305
TOTAL STOCKHOLDERS' EQUITY	**1,457**	**1,321**
Non-current liabilities		
Employee benefit liability	291	288
Deferred tax	911	970
Provisions	54	60
Deferred revenue and other non current liabilities	5	7
Financial institutions	3,977	4,275
TOTAL NON-CURRENT LIABILITIES	**5,238**	**5,600**
Current liabilities		
Financial institutions	253	238
Trade payables	235	265
Income tax payable	57	50
Provisions	207	209
Other payables	150	204
Deferred revenue	71	85
TOTAL CURRENT LIABILITIES	**973**	**1,051**
TOTAL LIABILITIES	**6,210**	**6,651**
TOTAL EQUITY AND LIABILITIES	7,668	7,972

Cash Flow

	Q2 2009 (€m)	Q2 2008 (€m)	H1 2009 (€m)	H1 2008 (€m)
Cash flow from operating activities				
Operating profit	74.7	178.7	205.6	261.7
Adjustments to reconcile operating profit to net cash flows:				
Depreciation and impairment of property, plant and equipment	20.8	20.4	41.0	40.7
Amortisation and impairment of intangible assets	153.8	136.8	304.7	332.1
Movements in provisions, pensions, and other liabilities	(14.6)	(37.4)	(8.2)	11.2
Other adjustments	(0.1)	0.2	(0.6)	(3.6)
Change in working capital	(19.6)	(66.9)	(60.4)	(64.4)
Income taxes received (paid)	(70.6)	(74.7)	(103.9)	(98.0)
Net cash flow from operating activities	144.4	157.1	378.2	479.7
Cash flow from investing activities				
Acquisition of subsidiaries [1, 2]		5.5	(6.4)	(222.6)
Purchase of intangible assets	(26.7)	(19.2)	(43.4)	(35.8)
Proceeds from sale of intangible assets	(0.2)	2.6	1.7	2.6
Purchase of property, plant and equipment	(18.6)	(17.9)	(27.2)	(29.7)
Proceeds from sale of tangible assets	0.3	1.0	1.1	1.0
Purchase of other investments	(0.2)	–	(0.2)	–
Net cash flow from investing activities	(45.4)	(28.1)	(74.3)	(284.5)
Cash flow from financing activities				
Repayment of financial institutions	(113.9)	(70.8)	(113.9)	(133.3)
Repayment of other borrowings	(6.9)	(5.5)	(7.4)	(5.5)
Acquisition of own shares from minority holders	(0.1)	–	(2.9)	–
Buyback of debt	(33.2)	–	(92.6)	–
Financial income received	4.2	–	8.4	–
Financial expenses paid	(46.1)	(81.5)	(128.6)	(166.5)
Unwinding of the cross currency swaps	(12.0)	–	(12.0)	–
Net cash flow from financing activities	(208.0)	(157.8)	(348.9)	(305.3)
Net cash flow	(109.0)	(28.8)	(45.0)	(110.2)
Cash as at beginning of period	560.2	402.9	496.7	484.2
Currency translation adjustments	2.1	–	1.6	–
Cash as at end of period	453.3	374.1	453.3	374.1

1) Acquisitions of 50.0% Nycomed Madaus (Pty) Ltd [South Africa] in 2009
2) Acquisition Bradley Pharmaceuticals Inc. [United States] in 2008

Notes

In this report, references to "we", "us", "our", "Nycomed" and "the Nycomed Group" are to Nycomed S.C.A. SICAR and its consolidated subsidiaries and affiliates, and with respect to periods prior to the acquisition of Altana Pharma AG, these terms refer to the proforma financial figures for Nycomed S.C.A. SICAR and its consolidated subsidiaries and affiliates.

This Interim Report has been drawn up in accordance with International Financial Reporting Standards (IFRS), as set forth in the Annual Report 2008. This discussion should be read in conjunction with the audited consolidated financial statement of Nycomed S.C.A. SICAR as of and for the twelve months ended 31 December 2008.

For further information, please see the Nycomed website.

Comparability of results

For comparative reasons, we have re-stated income statement and cash flow statement for the second quarter 2008 (April through June) and the first half 2008 (January through June).

Forward-looking statements

The forward-looking statements in this report reflect management's expectations of future events based on the information presently available to us and must be viewed in the context of the business environments, currency markets and regulatory developments which may cause actual results to deviate materially from those projected by Nycomed. For further information on factors, which may cause deviations, please see website: www.nycomed.com

Conference Call

Nycomed will host a conference call on August 19, 2009 at 3:00p.m. (CET).

To access, participants should dial one of the following phone numbers:

UK	+44 208 817 9301
US	+1 718 354 1226
Denmark	+45 70 26 5040
Ireland	+353 1 436 4265

This conference will be transcribed and digitally recorded. All participants who dial in will be requested to give their full name and company name for the conference call. These details will be requested to ensure the screening process for all participants.

The conference will be available in digital replay. This service will be available approximately two hours after the conference call has ended and will be available until September 26, 2009 23:59 PM GMT+02:00.

Digital replay phone number	+353 1 436 4267
Passcode	1987927#

Contacts

Håkan Björklund, CEO	+41 44 555 11 01
Runar Bjørklund, CFO	+41 44 555 11 03
Christian Seidelin, SVP, Corporate Finance	+41 44 555 11 04
Walter Vaterlaus, SVP, Corporate Communications	+41 44 555 15 10

Nycomed S.C.A., SICAR
412F, route d'Esch
L-1030 Luxembourg
www.nycomed.com